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Abstract. Background: To date an accurate evaluation of
predictive markers in breast cancer is mainly conducted at the
primary site, although the main goal of the adjuvant therapy is
the control of micrometastases. Adjuvant therapy drugs need a
high proliferative cell rate to be effective. The proliferating
activity can be evaluated by the Ki-67 marker and even by
thymidylate synthase (TS), a cell cycle enzyme present in
proliferating cells. In this study the TS levels in primary
tumours were compared to those of their metastases. Patients
and Methods: The TS expression and Ki-67 were evaluated by
means of immunohistochemistry in 80 primary breast tumours
(PTs) and in their matched axillary metastatic lymph-nodes
(ALNs). Results: In 16% of patients, malignant cells of
involved nodes showed a lower TS expression than the PTs. In
the same group, we also found a lower number of Ki-67
immunoreactive cells in lymph node metastases when
compared with primary tumours. Conclusion: The group of
patients with lower TS and Ki-67 expression in lymph node
metastatic cells may be less sensitive to 5-fluorouracil and high
dose methotrexate requiring them to be treated with other drug
combinations.
Breast cancer is the most frequent neoplasm in women of
Western countries and is the first cause of oncological
morbidity and mortality. This tumour is characterized by
strong variability, so therapeutically predictive biological
markers need to be identified. For breast cancer, many
prognostic markers that initially appeared promising have
failed to maintain their clinical predictive value. Few reports
have analysed the consistency over time of biological and
clinical information provided by biomarkers (1). In an
analysis of many individual parameters such as
differentiation, histotype and nuclear pleomorphism, it has
been shown that the presence of proliferative activity is the
strongest predictor of reduced survival and response to
treatment (2). There are many methods to assess
proliferative activity such as flow cytometric analysis of the
cells in the S-phase, the thymidine labeling index and
immunohistochemical analysis of proliferation antigens, of
which Ki-67 is the most frequently used. Thymidylate
synthase (TS) could also be considered a marker of
proliferation status since it is related to the percentage of
cells in the S-phase of the cell cycle (3). TS is the most
important target of 5-fluorouracil (5-FU), a drug which is
frequently used in chemotherapeutic combinations such as
for the treatment of breast cancer FAC, FEC, CMF.
Although much of the recent prognostic emphasis in breast
cancer patients has been related to node negative status (4),
it may be important to study the clinical, prognostic and
predictive features of axillary metastases. Even though
nodal status is the single most important predictor of distant
metastases and overall survival, this factor is not always
sufficient to allow a treatment decision to be made; in fact
for those patients who present axillary lymph node (ALN)
involvement, therapeutic options range from tamoxifene
alone to several anti neoplastic drug combination-based
protocols (5). To date, in breast cancer, both proliferation
index and the other immunohistochemical prognostic
factors (estrogen and progesterone receptors, C-Erb2, Mib-
1, p53) are exclusively assessed on the primary tumour (PT)
(6) while the main goal is the control of micrometastases.
In our opinion these features even in metastatic lymph
nodes could influence the clinician’s therapeutic choice.
The aim of this study was to evaluate as a therapeutic
and/or prognostic marker the proliferation status of the PTs
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and of the ALNs in 80 breast cancer node-positive patients
using the TS expression. The TS levels evaluated both in
PTs and in metastases could give important information not
only about the proliferation status of the tumours but could
also be predictive of the response to fluoropyrimidine drugs.
In order to confirm the predictive value of TS for
proliferation, the same group of patients already evaluated
for Ki-67 expression was chosen in which we had observed
that a small group of patients (16%) showed lower Ki-67
positivity in matched lymph nodes when compared with PTs
(7).
Patients and Methods
The clinical records of 80 patients with axillary positive nodes, who
had undergone surgery for previously untreated breast
adenocarcinoma, were reviewed. In a previous study the Ki-67
expression in these samples had been evaluated (7).
The cases comprised 43 ductal infiltrating carcinomas (CDI) (31
CDI, 8 mucinous carcinomas, 4 apocrine carcinomas), 26 lobular
infiltrating carcinomas, 4 lobular and ductal infiltrating carcinomas
and 7 tubulo-lobular carcinomas. All cases were in stage II
according to the UICC-TNM staging system (Table I).
Before starting the study, the patients’ consent was obtained. 
Our study was performed using formalin-fixed paraffin-
embedded primary tumour samples, retrieved from archival
material. For each case, four 3-mm sections that were dewaxed and
rehydrated were used. Antigen retrieval was carried out using Dako
(Glostrup, Denmark) antigen retrieval fluid and microwaving at
full power for 30 min, divided into 6 periods. The sections were
then treated with hydrogen peroxidase for 5 min, followed by TS
106 antibody at a dilution of 1:10 overnight at 4ÆC. Visualization
was obtained with a Dako visualization system. For metastatic
localization, as a positive internal control the follicle germinal
centres of lymph nodes were used, while for primary tumours a
sample of colorectal carcinoma was used as a positive external
control. The TS staining was evaluated as being positive when the
intensity of staining of the samples (cytoplasmatic and/or nuclear)
was greater than the intensity of staining of the respective control.
Finally, negative controls, lacking the primary antibody, were
included in each run. The TS staining positivity was evaluated in
10 microscopic high power fields (HPFs) in which the neoplastic
epithelial area was more than 70% of the whole field. The TS
staining positivity was evaluated semi-quantitatively as strong
positivity (++) if more than 50% of the neoplastic areas were
positive, mild positivity (+) if 10-50% of neoplastic areas were
positive and negativity (–) if less than 10% of the neoplastic areas
were positive.
Results
On the basis of our results, the patients were divided into
three groups. Category A; This consisted of 47 cases (59%)
with the following histological types: 29 infiltrating ductal
carcinomas, 2 mucinous carcinomas, 1 apocrine carcinoma,
13 infiltrating lobular carcinomas, 1 lobular – ductal
infiltrating carcinoma and 1 tubulo-lobular carcinoma. All
these cases showed an increased TS expression in the ALNs
when compared with PTs. Category B; This consisted of 20
cases (25%) with the following histological types: 5
infiltrating ductal carcinomas NOS, 1 mucinous carcinoma, 1
apocrine carcinoma, 10 infiltrating lobular carcinomas, 1
lobular–ductal infiltrating carcinoma and 2 tubulo-lobular
carcinomas. All these cases showed the same TS expression in
both the ALNs and the PTs. Category C; This consisted of 13
cases (16%) showing the following histological types: 6
infiltrating ductal carcinomas NOS, 1 mucinous carcinoma, 1
apocrine carcinoma, 3 infiltrating lobular carcinomas, 1
lobular–ductal infiltrating carcinoma and 1 tubulo-lobular
carcinoma. In this category, the cases showed a decreased TS
expression in ALNs when compared with the PTs.
The decrease of TS expression in the ALNs of category
C proved to be independent of the histotype and the
histological grade of the tumour. These data were
concordant with the Ki-67 findings (Figure 1).
Discussion 
The search for prognostic factors for breast cancer is largely
centred on node-negative disease, where about the 25% of
node-negative patients are destined to relapse despite the
treatment (4), and the goal of these studies has been to
direct treatment to the minority of patients who would
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Table I. Clinicopathological features of patients included in the study.
Patients N
Age (years) <35 25
>35 55
Stage II (UICC-TNM) 80
Grading G1 17
G2 30
G3 33
Histotype Ductal infiltrating carcinoma 43
Lobular infiltrating carcinoma 26
Lobular-ductal infiltrating carcinoma 4
Tubulo-lobular carcinoma 7
Table II. TS expression: ++, strong positive; +, mild positive; –, negative
in primary tumours (PTs) and in matched axillary lymph-nodes (ALNs).
PT – / ALN + PT ++ / ALN ++ PT ++ / ALN +
PT + / ALN ++ PT + / ALN + PT + / ALN – 
Category A 47 0 0 
Category B 0 20 0 
Category C 0 0 13
derive benefit from adjuvant chemotherapy. In contrast, the
vast majority of patients with node-positive breast cancer
can expect to receive adjuvant chemotherapy routinely.
Prognostic factors in this group have received less attention,
in large part because of the definite benefit derived from
adjuvant chemotherapy and the belief that additional
measures would have little impact on the prognosis
predicted by the presence of positive axillary lymph nodes. 
TS converts deoxyuridine monophosphate (dUMP) to
deoxythymidine monophosphate (dTMP), which is essential
for DNA biosynthesis and is a critical target for the
fluoropyrimidines and high dose methotrexate (HDMTX).
Both 5-FU and fluorodeoxyuridine are converted in tumour
cells to FdUMP which inactivates TS by the formation of a
ternary covalent complex in the presence of the folates
cofactor 5,10-methylenetetrahydrofolate; while MTX usually
inhibits dihydrofolate reductase abolishing the
tetrahydrofolate synthesis that usually transfers one carbon
group to d-uridine-monophosphate (d-UMP). In a key
metabolic event, d-UMP is converted to thymidylate, an
essential component of DNA, by TS. Expression of TS has
been shown to be associated with response to 5-FU in
human colorectal, gastric and breast cancer, in fact it is
widely accepted that high TS levels are associated with a
worse prognosis (8). However, some studies have shown
that some histological types of colorectal tumours, with the
worst prognosis such as the signet ring cell histotype, had
low TS levels (9) so patients with low TS expression also fail
to respond to treatment (6) (10). Our study showed that in
some patients (group C), breast primary carcinomas have a
high TS expression, while their matched ALNs have a lower
TS expression.
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Figure 1. 1A-1B ) Nuclear positive immunostaining for Ki-67 antibody is very rare in metastatic lymph nodes (1A) and very frequent in primary tumour
(1B) (x200). 1C-1D) Cytoplasmic positive immunostaining for TS antibody is absent in metastatic lymph node and present in primary tumor (x400). Note
for positive control lymphoid germinal centre (*), positive for both antibodies.
Our data showed the same relationship between TS
positivity and cell proliferation index as that assessed by the
Ki-67 levels. The low TS and Ki-67 values in some lymph
nodes, suggesting a low proliferative activity, was unexpected
due to the well known aggressiveness of metastases, thus
mechanisms other than proliferation could be responsible for
the escape of these cells. De la Haba et al. reported that in
60% of cases, the immunohistochemical expression of some
proteins such as estrogen, progesterone, Ki-67, p53, and
HER-2, was modified during tumour development and
dissemination, and led to immunophenotypical differences
between PTs and ALNs (11). They hypothesized that this
fact could be related to the intrinsic hetereogeneity of the
neoplastic cells. As different clones are present in primary
breast carcinomas, it is possible that only a small sub-
population of the PT cells metastasize. Buxant et al. found a
significantly higher proliferation index in ALNs than in PTs,
suggesting an increased aggressiveness of metastatic
neoplastic cells as compared to their PT counterparts. They
concluded that those cells with "the most aggressive potential
(like a high proliferative index) are the most likely to escape
from the primary tumour", or that "cells that escape from
primary tumour, lose down-regulator factors or suppressor
genes and become more aggressive" (12). On this basis, we
can hypothesize that metastatic node cells with low Ki-67
and TS contents could be less sensitive to 5-FU, because its
target is lacking. If this hypothesis is confirmed by other
clinical and experimental studies, the value of performing
imunohistochemical assessment of these markers not only in
PTs, but also in the respective metastases, should be
considered. 
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